Search

Displaying results 6501 - 6510 of 10000 in total
  1. Drug

    ABX1100

    go.drugbank.com/drugs/DB17655
    Investigational

    ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle.

  2. Drug

    Actelion-1

    go.drugbank.com/drugs/DB05367
    Experimental

    Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.

  3. Drug

    Talbutal

    go.drugbank.com/drugs/DB00306
    ApprovedIllicit

    Talbutal is a schedule III drug in the U.S.

  4. Drug

    Lestaurtinib

    go.drugbank.com/drugs/DB06469
    Investigational

  5. Drug

    Zandatrigine

    go.drugbank.com/drugs/DB19051
    Investigational

    Zandatrigine is under investigation in clinical trial NCT05226780 (Extension Study to Evaluate How Safe and Tolerable NBI-921352 Is as an Adjunctive Therapy for Participants With SCN8A-DEE).

    Synonyms: Benzenesulfonamide, 2-fluoro-5-methyl-4-(methyl((3s)-1-(phenylmethyl)-3-pyrrolidinyl)amino)-n-4-thiazolyl-
  6. Drug

    Indoprofen

    go.drugbank.com/drugs/DB08951
    ApprovedWithdrawn

    Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide.

  7. Drug

    Etazolate

    go.drugbank.com/drugs/DB05881
    Investigational

    EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.

  8. Drug

    NRP409

    go.drugbank.com/drugs/DB05235
    Experimental

    NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.

  9. Drug

    EpiVacCorona

    go.drugbank.com/drugs/DB16439
    Investigational

    EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus[L30608]. … It is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575)[L30608, L30613].

    Categories: Complex Mixtures
  10. Drug

    Mubodina

    go.drugbank.com/drugs/DB17616
    Experimental

    It was investigated in various conditions including primary membranoproliferative glomerulonephritis and typical hemolytic uremic syndrome. … Mubodina is an investigational drug developed by Adienne Pharma & Biotech. It is a recombinant human minibody directed against complement component C5.

    Synonyms: Neutralizing scFv dimer to C5 fused at the C terminal end to the Fc domains of human IgG1